Medical Affairs
Week ending August 28, 2026
1. Clinical accuracy snapshot
This is a baseline week with 9 questions and 63 answer variants; no prior-week comparison is available. Label-accuracy risk is high despite frequent hedging (56 tags). The most important issue is product and indication misidentification in PI answers: several responses describe Valchlor as valrubicin, verapamil, or other products, and incorrectly associate it with bladder cancer, actinic keratosis, vulvar cancer, or molluscum.
The dosing question shows the clearest clinical divergence. Answers generally state once-daily application, but treatment duration varies from 4 weeks to 6–12 weeks, while two answers provide an erroneous intravesical valrubicin 800-mg/6-week regimen. Valchlor is topical mechlorethamine gel; the label does not support presenting a fixed “usual” number of weeks as a universal regimen.
For application and skin-condition questions, answers generally converge on avoiding broken, infected, oozing, or actively inflamed skin. However, the inconsistency flags show uneven inclusion of contraindication/precaution language, and some responses use potentially inaccurate formal terminology such as “contraindicated.” The application answers also fail to consistently address the specific bandaging question and may provide unsupported product-specific instructions.
The nine inconsistency flags primarily represent omission variability, not nine separate confirmed fact conflicts. Nonetheless, the identity, indication, dosing, and administration errors are material clinical-accuracy concerns.
2. Off-label and substitution handling
Off-label handling is inconsistent. Seven off-label tags were recorded, concentrated in the Valchlor-versus-imiquimod and molluscum questions. Some answers appropriately state that molluscum is not an approved indication and should not be treated without clinician direction. Others say Valchlor “can be used” or is “prescribed” for molluscum, and several incorrectly identify its approved use. This blurs approved versus unapproved use and could encourage inappropriate self-treatment.
Substitution questions generated five “compounded” tags but no competitor mentions and no biosimilar/generic tags. Answers discuss “different strengths/formulations” and compounded products without establishing whether a product is therapeutically equivalent, interchangeable, or supported by the Valchlor label. This suggests a need for a clear substitution response rather than evidence of a competitor-driven trend.
3. Unmet information needs
Priority information needs are:
- Correct product identity and approved indication, including distinguishing mechlorethamine gel from similarly named products.
- Exact application instructions, including amount, drying time, handwashing, storage, and whether to cover the treated area.
- What to do with broken, infected, oozing, or eczematous skin, including when to pause and contact the prescriber.
- Expected duration and reassessment, with clear explanation that treatment is not defined by a universal 4-, 6-, or 12-week course.
- Valchlor versus other topical therapies, especially how to discuss “stronger” without implying superiority or making unsupported efficacy comparisons.
- Off-label requests such as molluscum, with explicit approved-use boundaries and referral language.
4. Change over time
No rise or fall can be determined because this is the first available week. Current baseline levels are 9 inconsistency flags, 7 off-label tags, and 5 compounded tags. The apparent new pattern is widespread name/product confusion across PI answers, rather than a demonstrated week-over-week change.
5. Recommended actions
- Urgently update the Medical Information standard response for dosing/application, including label-consistent once-daily use, no universal treatment duration, and bandaging instructions.
- Escalate product-identity and indication errors to Regulatory/Medical review; create a controlled “Valchlor facts” reference covering ingredient, strength, dosage form, indication, and route.
- Develop an off-label response module for molluscum and imiquimod comparisons that clearly separates approved use, off-label use, evidence limitations, and clinician supervision.
- Create a substitution FAQ addressing compounded mechlorethamine and the limits of assuming equivalence or interchangeability.
- Provide HCP-facing counseling language for “Is it stronger?” and for managing treatment on irritated or compromised skin.